文献速递技术与安全MR

对比增强MRI检查中钆基对比剂被血细胞摄取的研究

Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination.
PubMed 文献 · Invest Radiol · 2023-10-13

本研究将人血体外暴露于钆特酸葡胺(Gd-DOTA)或Eu-DOTA,并采集接受Gd-DOTA增强MRI患者血样,用单细胞电感耦合等离子体质谱(SC-ICP-MS)和时间分辨荧光光谱检测血细胞摄取。体外和体内均发现白细胞摄取Gd-DOTA/Eu-DOTA,红细胞未检测到摄取;42例患者白细胞Gd摄取呈不均匀分布,范围为21–444阿克/白细胞。

要点

  • 增强MRI后白细胞可检测到钆摄取,红细胞未检测到摄取。
  • 患者白细胞钆摄取呈不均匀分布,范围为21–444阿克/白细胞。
  • 钆摄取与钆沉积的关联尚不明确。

核心结论

  • 本研究证实GBCA在体外可被白细胞摄取,并首次提供GBCA在体内确实被接受增强MRI检查患者白细胞摄取的证据。
  • 观察到的白细胞钆摄取不遵循环境科学、生物学和医学中常见的对数正态分布。
  • GBCA的细胞摄取是否与观察到的钆沉积相关尚不清楚。
  • 研究GBCA与人细胞的相互作用可能有助于阐明MRI检查后钆对患者影响的关键问题。

研究设计与样本

  • 研究类型为体外实验联合患者体内观察性研究,原文未明确写研究设计类型。
  • 体外实验将人血暴露于钆特酸葡胺(Gd-DOTA)或Eu-DOTA。
  • 体内研究纳入42例接受Gd-DOTA增强MRI检查的患者,年龄30至84岁,其中男24例、女18例。
  • 采用单细胞电感耦合等离子体质谱(SC-ICP-MS)定量血细胞对对比剂的摄取,并用时间分辨荧光光谱通过Eu-DOTA确认Gd-DOTA摄取。

诊断标准与关键数值

  • 体外实验中,SC-ICP-MS和时间分辨荧光光谱均可检测到白细胞对Gd-DOTA或Eu-DOTA的摄取,估计细胞内浓度范围为1–3 μM。
  • 两种方法均未检测到红细胞对对比剂的摄取。
  • 患者白细胞Gd摄取由SC-ICP-MS测定,MRI检查后立即测量为21–444阿克/白细胞,对应细胞内Gd浓度范围为0.2–5.5 μM。

局限性

  • 观察到的白细胞钆摄取不遵循环境科学、生物学和医学中常见的对数正态分布。
  • GBCA的细胞摄取是否与观察到的钆沉积相关尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI) examinations. However, there is limited knowledge about the interaction with and distribution of the drug in human cells. This lack of knowledge is surprising, given that the first interaction of the drug occurs with blood cells. Moreover, recent studies reported gadolinium (Gd) deposition within organs, such as the brain. Hence, this study is aiming to determine the uptake of GBCA in blood cells of patients undergoing contrast-enhanced MRI (ce-MRI) examination.

MATERIALS AND METHODS: Human blood was exposed to either gadoterate meglumine (Gd-DOTA) or Eu-DOTA in vitro or was collected from patients undergoing ce-MRI with Gd-DOTA. Uptake of contrast agents (CAs) by blood cells was quantified by Gd measurements using single-cell inductively coupled plasma mass spectrometry (SC-ICP-MS) or, to confirm Gd-DOTA uptake, by a complementary method using Eu-DOTA by time-resolved fluorescence spectroscopy, respectively.

RESULTS: Uptake of Gd-DOTA or Eu-DOTA into white blood cells (WBCs) ex vivo was detectable by SC-ICP-MS and time-resolved fluorescence spectroscopy. The intracellular concentrations were estimated to be in the range of 1-3 μM. However, no CA uptake into erythrocytes was detected with either method. In total, 42 patients between 30 and 84 years old (24 men, 18 women) were enrolled. White blood cells' uptake of Gd was measured by SC-ICP-MS. Isolated WBCs from patients who underwent ce-MRI examination showed substantial Gd uptake; however, the studied patient group showed an inhomogeneous distribution of Gd uptake. Measurements immediately after MRI examination indicated 21-444 attogram/WBC, corresponding to an intracellular Gd concentration in the range from 0.2 to 5.5 μM.

CONCLUSIONS: This study confirms the ex vivo uptake of GBCA by WBCs and provides the first evidence that GBCA is indeed taken up by WBCs in vivo by patients undergoing ce-MRI examination. However, the observed Gd uptake in WBCs does not follow a log-normal distribution commonly observed in the fields of environmental studies, biology, and medicine. Whether cellular uptake of GBCA is linked to the observed deposition of Gd remains unclear. Therefore, studying the interaction between GBCA and human cells may clarify crucial questions about the effects of Gd on patients after MRI examinations.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Ruprecht N, Parakkattel D, Hofmann L, et al. Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination. Invest Radiol. 2023. PMID: 37824716. doi:10.1097/RLI.0000000000001029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。